Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

enzalutamide 92Magnetic Resonance Spectroscopy 87Specimen Handling 66Prednisone 65Androgen Antagonists 59Abiraterone Acetate 59apalutamide 56Radiosurgery 53Radiotherapy 47Leuprolide 47darolutamide 46abiraterone 44Docetaxel 43Radiation 31Pluvicto 31acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 30Biopsy 30relugolix 28Surveys and Questionnaires 28pembrolizumab 26gallium 68 PSMA-11 26Standard of Care 26Triptorelin Pamoate 25Goserelin 25bicalutamide 23Gonadotropin-Releasing Hormone 23Brachytherapy 21Carboplatin 20X-Rays 19luprolide acetate gel depot 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Robotics × 1 year × Clear all
NCT06389786 2026-04-06

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Mayo Clinic

Phase NA Recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT07025369 2026-03-13

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Mayo Clinic

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡